+

WO2006113898A3 - Tetrapeptides pif - Google Patents

Tetrapeptides pif Download PDF

Info

Publication number
WO2006113898A3
WO2006113898A3 PCT/US2006/014969 US2006014969W WO2006113898A3 WO 2006113898 A3 WO2006113898 A3 WO 2006113898A3 US 2006014969 W US2006014969 W US 2006014969W WO 2006113898 A3 WO2006113898 A3 WO 2006113898A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptides
pif
tetrapeptides
disclosed
peptidomimetics
Prior art date
Application number
PCT/US2006/014969
Other languages
English (en)
Other versions
WO2006113898A2 (fr
Inventor
Eytan R Barnea
Original Assignee
Bioincept Llc
Eytan R Barnea
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioincept Llc, Eytan R Barnea filed Critical Bioincept Llc
Priority to EP06750884.6A priority Critical patent/EP1879604B1/fr
Publication of WO2006113898A2 publication Critical patent/WO2006113898A2/fr
Publication of WO2006113898A3 publication Critical patent/WO2006113898A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des peptides et des substances mimétiques peptidiques permettant d'accroître la réceptivité endométriale, de bloquer une immunité activée mais non basale, d'inhiber une prolifération cellulaire et de créer une affinité pour les cytokines de type TH2, les peptides et les substances mimétiques susmentionnés sont fondés sur le tétrapeptide C-terminal de peptides PIF. L'invention concerne également des méthodes d'utilisation de ces peptides et de ces substances mimétiques peptidiques à des fins thérapeutiques et diagnostiques.
PCT/US2006/014969 2005-04-20 2006-04-20 Tetrapeptides pif WO2006113898A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06750884.6A EP1879604B1 (fr) 2005-04-20 2006-04-20 Tetrapeptides pif

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/110,990 US7723289B2 (en) 2003-10-22 2005-04-20 PIF tetrapeptides
US11/110,990 2005-04-20

Publications (2)

Publication Number Publication Date
WO2006113898A2 WO2006113898A2 (fr) 2006-10-26
WO2006113898A3 true WO2006113898A3 (fr) 2009-05-07

Family

ID=37115959

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/014969 WO2006113898A2 (fr) 2005-04-20 2006-04-20 Tetrapeptides pif

Country Status (3)

Country Link
US (1) US7723289B2 (fr)
EP (1) EP1879604B1 (fr)
WO (1) WO2006113898A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8222211B2 (en) * 2001-07-02 2012-07-17 Bioincept, Llc Methods of administering PIF agonist peptides and uses thereof
EP1404877B1 (fr) * 2001-07-02 2010-01-06 Bioincept, LLC. Dosages pour le facteur preimplantatoire et peptides du facteur preimplantatoire
US7723290B2 (en) 2004-10-22 2010-05-25 Bioincept, Llc Compositions and methods for modulating the immune system
EP2680872B1 (fr) 2011-03-02 2018-08-15 BioIncept LLC Compositions et procédés pour traiter des lésions intracellulaires
EP3060924B1 (fr) 2013-10-22 2022-06-01 Bioincept LLC Cellules transfectées par un pif et procédés d'utilisation
WO2017079430A1 (fr) * 2015-11-03 2017-05-11 Bioincept, Llc Peptides et méthodes de traitement de l'endométriose utilisant lesdits peptides
JP2017535794A (ja) * 2014-11-03 2017-11-30 バイオインセプト、エルエルシー 免疫調節不全についてのマーカーとしてのｐｉｆ結合
CA2996874A1 (fr) 2015-08-28 2017-03-09 Bioincept, Llc Compositions et methodes pour le traitement d'une lesion neurologique
EP3341739A4 (fr) * 2015-08-28 2019-07-10 BioIncept LLC Peptides mutants et procédés de traitement de sujets les employant
CA3054366A1 (fr) 2017-02-22 2018-08-30 Bioincept, Llc Peptides et methodes de traitement d'affections liees a la dystrophie les utilisant
EP3999846A4 (fr) 2019-07-25 2023-08-09 Overture Life, Inc Identification d'embryons humains viables
US20230400471A1 (en) * 2020-10-15 2023-12-14 Bioincept, Llc Systems, compositions and methods of determining viability of embryos using the same
EP4248985A1 (fr) 2022-03-25 2023-09-27 Consejo Superior de Investigaciones Científicas (CSIC) Peptides pour le traitement de la rétinite pigmentaire

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030099643A1 (en) * 1988-11-23 2003-05-29 Carl H. June Methods for selectively stimulating proliferation of t cells
US20050064520A1 (en) * 2001-07-02 2005-03-24 Barnea Eytan R. New assays for preimplantation factor and preimplantation factor peptides

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5279941A (en) * 1992-06-12 1994-01-18 Trustees Of The University Of Pennsylvania Determination of endometrial receptivity toward embryo implantation
US5646003A (en) 1994-03-23 1997-07-08 Barnea; Eytan R. Preimplantation factor
GB9406492D0 (en) * 1994-03-31 1994-05-25 Isis Innovation Malaria peptides
US6585979B1 (en) 1996-07-08 2003-07-01 Genentech, Inc. HIV envelope polypeptides and immunogenic composition
KR20030070092A (ko) * 2001-01-04 2003-08-27 바스큘라 바이오제닉스 리미티드 죽상경화증을 예방 및 치료하기 위한 플라크 관련 분자를함유하는 조성물 및 이 분자를 이용하는 방법
US8222211B2 (en) 2001-07-02 2012-07-17 Bioincept, Llc Methods of administering PIF agonist peptides and uses thereof
ES2498371T3 (es) 2002-12-06 2014-09-24 Epimmune Inc. Antígenos de Plasmodium falciparum y procedimientos de uso
NZ547139A (en) 2003-10-22 2009-12-24 Bioincept Llc Use of preimplantation factor peptides to treat intolerence to embryo implantation
US7723290B2 (en) 2004-10-22 2010-05-25 Bioincept, Llc Compositions and methods for modulating the immune system

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030099643A1 (en) * 1988-11-23 2003-05-29 Carl H. June Methods for selectively stimulating proliferation of t cells
US20050064520A1 (en) * 2001-07-02 2005-03-24 Barnea Eytan R. New assays for preimplantation factor and preimplantation factor peptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BARNEA: "Insight into Early Pregnancy Events: The Emerging Role of the Embryo.", AM. J. REPROD. IMMUNOL., vol. 51, 2004, pages 319 - 322, XP008123722 *

Also Published As

Publication number Publication date
EP1879604A2 (fr) 2008-01-23
US7723289B2 (en) 2010-05-25
WO2006113898A2 (fr) 2006-10-26
US20080003178A1 (en) 2008-01-03
EP1879604B1 (fr) 2020-06-03
EP1879604A4 (fr) 2012-01-18

Similar Documents

Publication Publication Date Title
WO2006113898A3 (fr) Tetrapeptides pif
AU2003265276A8 (en) Iap binding compounds
WO2006097536A3 (fr) Agonistes a base de peptide dimere contre le recepteur de glp-1
WO2008018792A3 (fr) Analogues d'angiotensine cycliques
HK1084604A1 (en) Angiotensin-converting enzyme inhibitory peptides
WO2008030558A3 (fr) Polypeptide plasmatique humain modifié ou squelettes de fc et leurs utilisations
EP2949658A3 (fr) Peptides qui lient spécifiquement le récepteur HGF (CMET) et utilisations associées
EP1751179A4 (fr) Peptides derives de la caseine et leurs utilisations therapeutiques
WO2007120311A3 (fr) Détection de peptides solubles du récepteur de l'adiponectine et utilisation dans le diagnostic et la thérapeutique
MXPA03010762A (es) Peptidos enlazantes de iap y ensayos para identificar los compuestos que enlazan el iap.
WO2006066024A3 (fr) Motifs de famille de polypeptides pancreatiques, polypeptides et leurs methodes
IL183107A0 (en) Tripeptide and tetrapeptide thioethers
WO2003074546A3 (fr) Peptide de liaison a la streptavidine
WO2004111087A3 (fr) Proteine thap1 fixatrice des chimiokines, methodes et utilisations de celle-ci
MXPA05011783A (es) Peptidos que tienen un efecto inhibidor de enzima convertidora de angiotensina.
EP1499635B8 (fr) Peptides associes au terminal c de teneurines (tcap) et leurs procedes d'utilisation
CA3080256A1 (fr) Peptides wnt5a utilises dans la reduction de cellules souches cancereuses
WO2007052173A3 (fr) Activite des domaines de liaison des chimiokines de la famille des thap
WO2003054009A3 (fr) Peptides ayant un effet sur l'apoptose
WO2004069875A3 (fr) Immunoglobuline
ATE438311T1 (de) Peptide mit ace-hemmwirkung
AU2003201798A1 (en) Hif-1 alpha proteins mutated in the c-terminal transactivation domain
AU2002951829A0 (en) The streptococcal peptides and uses therefor
GB0521490D0 (en) RFamide-related peptide precursor proteins and RFamide peptides
WO2005010205A3 (fr) Biomarqueurs nouveaux de l'activite de l'agrecanase

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006750884

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: RU

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载